Inventor · disambiguated record

Xunqiang Wang

Also filed as: WANG XUNQIANG

11 granted patents·19 pending applications·49 citations·filing 2015–2025

88Inventor score

Files withCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD27 NANJING SHUNXIN PHARMACEUTICALS CO LTD OF CHIATAI TIANQING PHARMACEUTICAL GROUP2 NANJING SHUNXIN PHARMACEUTICALS CO LTD OF CHIATAI TIANQING PHARM GROUP1

Top patents by PatentIndex Score

30 records

0191US10307412B2Quinoline derivative against non-small cell lung cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Jun 4, 2019·6 cites·16 claims
0291US9968597B2Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of sameCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted May 15, 2018·13 cites·20 claims
0389US10183017B2Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of sameCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2018·Granted Jan 22, 2019·9 cites·20 claims
0488US11419862B2Quinoline derivative for treatment of nasopharyngeal carcinomaCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2020·Granted Aug 23, 2022·3 cites·22 claims
0588US10888559B2Quinoline derivatives for non-small cell lung cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Jan 12, 2021·3 cites·18 claims
0686US10736887B2Quinoline derivative for treating gastric cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Aug 11, 2020·3 cites·13 claims
0786US10251876B2Method for treating tumour, pharmaceutical composition and medicinal kitCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Apr 9, 2019·7 cites·15 claims
0885US11554115B2Quinoline derivative for treatment of triple-negative breast cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Granted Jan 17, 2023·2 cites·20 claims
0979US10561647B2Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereofCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Feb 18, 2020·3 cites·15 claims
1070US2025367187A1Quinoline derivative used for treating small cell lung cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2025·Application pending·0 cites
1164US2025282873A1Drug combination of anti-tim-3 antibody and anti-pd-1 antibodyNANJING SHUNXIN PHARMACEUTICALS CO LTD OF CHIATAI TIANQING PHARMACEUTICAL GROUP·Filed 2023·Application pending·0 cites
1263US2022031689A1Quinoline derivative used for treating small cell lung cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Application pending·0 cites
1361US2025295765A1Drug combination for treating non-small cell lung cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2022·Application pending·0 cites
1460US12447154B2Use of pyrrolopyrimidine compound for treating hemophagocytic syndromeCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Granted Oct 21, 2025·0 cites·20 claims
1560US2024343807A1Pharmaceutical composition for treating small cell lung cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2022·Application pending·0 cites
1660US2025295662A1Use of cdk4/6 inhibitor in treatment of dedifferentiated liposarcomaCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2023·Application pending·0 cites
1760US2025213570A1Use of pyrrolopyrimidine compound in treatment of medium-risk or high-risk myelofibrosisCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2023·Application pending·0 cites
1860US2024269278A1Anti-cd47 antibody for combined treatment of blood tumorNANJING SHUNXIN PHARMACEUTICALS CO LTD OF CHIATAI TIANQING PHARMACEUTICAL GROUP·Filed 2022·Application pending·0 cites
1958US2025230242A1Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agentNANJING SHUNXIN PHARMACEUTICALS CO LTD OF CHIATAI TIANQING PHARM GROUP·Filed 2023·Application pending·0 cites
2058US2024285635A1Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host diseaseCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2022·Application pending·0 cites
2155US2023310596A1Drug for treating tumorCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Application pending·0 cites
2255US2023321104A1Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphomaCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Application pending·0 cites
2355US2023227556A1Combination drug for treating kidney cancerCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Application pending·0 cites
2454US2023263795A1Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibodyCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Application pending·0 cites
2550US2023119759A1Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compoundCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Application pending·0 cites
2650US2019269671A1Method for treating tumour, pharmaceutical composition and medicinal kitCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2019·Application pending·0 cites
2748US2023132982A1Use of pyrido[1,2-a]pyrimidinone compound in treating lymphomaCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Application pending·0 cites
2846US12421313B2Combined pharmaceutical composition for treating tumorCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2020·Granted Sep 23, 2025·0 cites·20 claims
2946US2022193067A1Quinoline compound or pharmaceutically acceptable salt thereof for treating ewing's sarcomaCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2020·Application pending·0 cites
3043US2020316053A1Application of novel tyrosine kinase inhibitor, anlotinib, in osteosarcoma and chondrosarcomaCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2020·Application pending·0 cites

Join the waitlist — get patent alerts

Get an alert when Xunqiang Wang files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →